Skip to Main content Skip to Navigation
Master Thesis

Maintien thérapeutique de l'Ustekinumab et du Secukinumab dans le rhumatisme psoriasique et la spondylarthrite axiale comparativement aux anti-TNF, en vie réelle

Abstract : Objectives : Ustekinumab (UST) and Secukinumab (SEC) have been recently added to the therapeutic arsenal for the treatment of patients with axial and/or peripheral spondyloarthritis. However, their place remains to be defined with respect to anti-TNFs. The aim of our study is therefore to evaluate the drug survival of these molecules in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in real life, compared to TNF antagonists. Methods: monocentric retrospective study including all patients with PsA or axSpA diagnosis received from UST, SEC or TNF inhibitor between 22/06/2019 and 31/12/2018, with follow-up until June 2019. Drug survival was evaluated at 6 months (M6), 12 months (M12) and 24 months (M24). Causes of arrest have been classified as lacking effectiveness, adverse effects or other. Results: 240 patients were included: 57 RA and 183 axSpA. The median of global maintenance was 10 months. Regarding PsA, 16 received from UST, 20 from SEC and 21 from TNF with a maintenance comparable to M6, M12 and M24. For axSpA, 31 received SEC and 152 TNF-antagonist with maintenance also comparable to each assessment. Therapeutic line and csDMARD combination were not associated with better maintenance of UST and SEC. Lack of efficacy was the first cause of arrest of these molecules. Conclusion: our real-life study suggests equivalent therapeutic maintenance of UST, SEC and TNF blockers. However, larger studies are needed to assert these results.
Complete list of metadatas

Cited literature [90 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-02510797
Contributor : Médecine Ub <>
Submitted on : Wednesday, March 18, 2020 - 10:54:34 AM
Last modification on : Saturday, March 21, 2020 - 1:17:07 AM
Long-term archiving on: : Friday, June 19, 2020 - 12:55:41 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-10-02

Please log in to resquest access to the document

Identifiers

  • HAL Id : dumas-02510797, version 1

Collections

Citation

Céline Labadie. Maintien thérapeutique de l'Ustekinumab et du Secukinumab dans le rhumatisme psoriasique et la spondylarthrite axiale comparativement aux anti-TNF, en vie réelle. Sciences du Vivant [q-bio]. 2019. ⟨dumas-02510797⟩

Share

Metrics

Record views

36